A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Nanosomal Docetaxel Lipid Suspension (75 mg/m2)|DRUG: Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|DRUG: Taxotere® (100 mg/m2)
Sponsor: Jina Pharmaceuticals Inc.
Collaborators: Intas Pharmaceuticals, Ltd.|Lambda Therapeutic Research Ltd.